Latest News and Press Releases

MELBOURNE, Australia, March 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to correct a misleading halt announcement released over the wire yesterday. ...

Key Highlights: Immuron’s flagship product Travelan® reports revenue in excess of AUS$914K for first 6mths of FY2018  Travelan® US experienced a 250% increase in sales year over year reaching...

Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of...

Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences...

Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...

MELBOURNE, Australia, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to advise investors that CEO Dr Jerry Kanellos, was interviewed on The...

MELBOURNE, Australia, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to advise investors that CEO Dr Jerry Kanellos is scheduled to present at...

MELBOURNE, Australia, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (the “Company”) wishes to advise investors that Van Leeuwenhoeck Institute, a prominent European and US-based Life...

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...

MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...